Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs ...
Medical Xpress

Considering the patient's perspective in inducible laryngeal obstruction care

Inducible laryngeal obstruction is a breathing disorder characterized by unwanted vocal fold closure, which has the potential to restrict breathing at times. It's estimated that between 3 and 12% of ...
EurekAlert!

MD Anderson acquires inducible switch technologies for cell therapy

HOUSTON ― The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDe® switch platform and the GoCAR ® ...

Novartis Pharma AG: Novartis RemIND data at EAACI show Rhapsido potential as first targeted therapy for chronic inducible urticaria (CIndU)

Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety concerns2Wit ...
EurekAlert!

Considering the patient’s perspective in inducible laryngeal obstruction care

Inducible laryngeal obstruction is a breathing disorder characterized by unwanted vocal fold closure having the potential to restrict breathing at times. It’s estimated that between 3-12% of patients ...